Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease.

Coletto E, Dolan JS, Pritchard S, Gant A, Hikima A, Jackson MJ, Benham CD, Chaudhuri KR, Rose S, Jenner P, Iravani MM.

NPJ Parkinsons Dis. 2019 Jun 10;5:10. doi: 10.1038/s41531-019-0081-9. eCollection 2019.

2.

The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.

Fisher R, Lincoln L, Jackson MJ, Abbate V, Jenner P, Hider R, Lees A, Rose S.

Phytother Res. 2018 Apr;32(4):678-687. doi: 10.1002/ptr.6017. Epub 2018 Jan 24.

PMID:
29368409
3.

Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.

Modo M, Crum WR, Gerwig M, Vernon AC, Patel P, Jackson MJ, Rose S, Jenner P, Iravani MM.

PLoS One. 2017 Jul 24;12(7):e0180733. doi: 10.1371/journal.pone.0180733. eCollection 2017.

4.

Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia.

Pritchard S, Jackson MJ, Hikima A, Lione L, Benham CD, Chaudhuri KR, Rose S, Jenner P, Iravani MM.

PLoS One. 2017 May 17;12(5):e0175797. doi: 10.1371/journal.pone.0175797. eCollection 2017.

5.

Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.

Lincoln L, Fisher R, Jackson MJ, Jenner P, Neumeyer J, Sromek AW, Lees AJ, Rose S.

Mov Disord. 2016 Sep;31(9):1381-8. doi: 10.1002/mds.26626. Epub 2016 May 2. Review.

PMID:
27133947
6.

Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity.

Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P.

J Mol Neurosci. 2014 Feb;52(2):302-12. doi: 10.1007/s12031-013-0145-y. Epub 2013 Oct 23.

PMID:
24150990
7.

An evaluation of the effectiveness of a commercial mechanical trap to reduce abundance of adult nuisance mosquito populations.

Jackson MJ, Gow JL, Evelyn MJ, McMahon TJ, Howay TJ, Campbell H, Blancard J, Thielman A.

J Am Mosq Control Assoc. 2012 Dec;28(4):292-300.

PMID:
23393751
8.

Evidence for abundant isolated magnetic nanoparticles at the Paleocene-Eocene boundary.

Wang H, Kent DV, Jackson MJ.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):425-30. doi: 10.1073/pnas.1205308110. Epub 2012 Dec 24.

9.

Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.

Tayarani-Binazir KA, Jackson MJ, Strang I, Jairaj M, Rose S, Jenner P.

Behav Pharmacol. 2012 Apr;23(2):126-33. doi: 10.1097/FBP.0b013e32834f9f82.

PMID:
22236652
10.

A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.

Hansard MJ, Jackson MJ, Smith LA, Rose S, Jenner P.

Behav Pharmacol. 2011 Jun;22(3):269-74. doi: 10.1097/FBP.0b013e328345ca37.

PMID:
21522056
11.

Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.

Zeng BY, Iravani MM, Jackson MJ, Rose S, Parent A, Jenner P.

Neurobiol Dis. 2010 Dec;40(3):599-607. doi: 10.1016/j.nbd.2010.08.004. Epub 2010 Aug 14.

PMID:
20713157
12.

The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.

Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.

Eur J Pharmacol. 2010 Jun 10;635(1-3):109-16. doi: 10.1016/j.ejphar.2010.03.006. Epub 2010 Mar 19.

PMID:
20303948
13.

Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.

Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P.

Mov Disord. 2010 Feb 15;25(3):377-84. doi: 10.1002/mds.22960.

PMID:
20108359
14.

The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.

Zubair M, Jackson MJ, Tayarani-Binazir K, Stockwell KA, Smith LA, Rose S, Olanow W, Jenner P.

Exp Neurol. 2007 Dec;208(2):177-84. Epub 2007 May 8.

PMID:
17935716
15.

Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.

Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ.

Mov Disord. 2007 Apr 15;22(5):715-9.

PMID:
17373723
16.

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.

Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P.

Exp Neurol. 2007 Mar;204(1):162-70. Epub 2006 Nov 16.

PMID:
17113078
17.

TBT causes regime shift in shallow lakes.

Sayer CD, Hoare DJ, Simpson GL, Henderson AC, Liptrot ER, Jackson MJ, Appleby PG, Boyle JF, Jones II, Waldock MJ.

Environ Sci Technol. 2006 Sep 1;40(17):5269-75.

PMID:
16999098
18.

Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease.

Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P.

Brain Res. 2006 Nov 6;1118(1):239-50. Epub 2006 Sep 7.

PMID:
16962083
19.
20.

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.

Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.

Eur J Pharmacol. 2006 Sep 28;546(1-3):82-7. Epub 2006 Jul 25.

PMID:
16925991

Supplemental Content

Loading ...
Support Center